应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
FTH Faeth Therapeutics
盘后交易 06-24 16:56:24 EDT
24.54
+0.54
+2.25%
盘后
24.54
+0.00
0.00%
16:10 EDT
最高
27.77
最低
24.05
成交量
10.28万
今开
24.05
昨收
24.00
日振幅
15.50%
总市值
6.33亿
流通市值
1,992万
总股本
2,578万
成交额
265.54万
换手率
12.67%
流通股本
81.17万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Sensei Biotherapeutics:Piktor治疗HR+/HER2-晚期乳腺癌的1B/2期中期数据预计2027年公布
美股速递 · 06-15
Sensei Biotherapeutics:Piktor治疗HR+/HER2-晚期乳腺癌的1B/2期中期数据预计2027年公布
Sensei Biotherapeutics:Piktor治疗晚期子宫内膜癌的II期关键数据预计2026年下半年公布
美股速递 · 06-15
Sensei Biotherapeutics:Piktor治疗晚期子宫内膜癌的II期关键数据预计2026年下半年公布
Sensei Biotherapeutics任命Anand Parikh为董事长、总裁兼首席执行官,自2026年6月12日起生效
美股速递 · 06-15
Sensei Biotherapeutics任命Anand Parikh为董事长、总裁兼首席执行官,自2026年6月12日起生效
Sensei Biotherapeutics更名为Faeth Therapeutics,全力推进口服抗癌疗法Piktor
美股速递 · 06-15
Sensei Biotherapeutics更名为Faeth Therapeutics,全力推进口服抗癌疗法Piktor
加载更多
公司概况
公司名称:
Faeth Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Faeth Therapeutics, Inc.是一家临床阶段的免疫疗法公司,于2017年12月1日在特拉华州注册成立。该公司是一家免疫肿瘤学公司,专注于癌症患者下一代疗法的发现和开发。通过TMAb(肿瘤微环境激活生物制剂)平台,公司正在开发高选择性疗法,旨在在肿瘤微环境中选择性地禁用免疫抑制信号或激活免疫刺激信号,以释放T细胞对抗肿瘤。
发行价格:
--
{"stockData":{"symbol":"FTH","market":"US","secType":"STK","nameCN":"Faeth Therapeutics","latestPrice":24.54,"timestamp":1782331200000,"preClose":24,"halted":0,"volume":102819,"hourTrading":{"tag":"盘后","latestPrice":24.54,"preClose":24.54,"latestTime":"16:10 EDT","volume":386,"amount":9472.44,"timestamp":1782331805188,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.022499999999999964,"floatShares":811700,"shares":25778800,"eps":-142.7282,"marketStatus":"盘后交易","change":0.54,"latestTime":"06-24 16:56:24 EDT","open":24.05,"high":27.77,"low":24.05,"amount":2655382,"amplitude":0.155,"askPrice":28.8,"askSize":70,"bidPrice":24,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-142.7282,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1782345600000},"marketStatusCode":4,"adr":0,"listingDate":1612414800000,"exchange":"NASDAQ","adjPreClose":24,"preHourTrading":{"tag":"盘前","latestPrice":23.11,"preClose":24,"latestTime":"09:22 EDT","volume":56,"amount":1337.459928,"timestamp":1782307368421,"change":-0.89,"changeRate":-0.037083,"amplitude":0.037083},"postHourTrading":{"tag":"盘后","latestPrice":24.54,"preClose":24.54,"latestTime":"16:10 EDT","volume":386,"amount":9472.44,"timestamp":1782331805188,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.814321},"requestUrl":"/m/hq/s/FTH","defaultTab":"news","newsList":[{"id":"1155638133","title":"Sensei Biotherapeutics:Piktor治疗HR+/HER2-晚期乳腺癌的1B/2期中期数据预计2027年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1155638133","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155638133?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:12","pubTimestamp":1781525543,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics公司宣布,其候选疗法Piktor针对HR阳性、HER2阴性晚期乳腺癌的1B/2期临床试验中期数据,预计将于2027年获得。该数据将提供关于疗法安全性及初步疗效的关键见解。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197135575","title":"Sensei Biotherapeutics:Piktor治疗晚期子宫内膜癌的II期关键数据预计2026年下半年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1197135575","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197135575?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:12","pubTimestamp":1781525543,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics公司宣布,其候选药物Piktor针对晚期子宫内膜癌的II期临床试验关键性数据,预计将于2026年下半年公布。这一时间表为关注该疗法进展的投资者和医学界提供了明确的时间节点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTH","BK4139","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110665123","title":"Sensei Biotherapeutics任命Anand Parikh为董事长、总裁兼首席执行官,自2026年6月12日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1110665123","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110665123?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:11","pubTimestamp":1781525508,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics, Inc. (SNSE) 宣布,自2026年6月12日起,Anand Parikh将正式出任公司董事长、总裁兼首席执行官。此项任命标志着公司领导层的重要更迭。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH","SNSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139331227","title":"Sensei Biotherapeutics更名为Faeth Therapeutics,全力推进口服抗癌疗法Piktor","url":"https://stock-news.laohu8.com/highlight/detail?id=1139331227","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139331227?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:10","pubTimestamp":1781525426,"startTime":"0","endTime":"0","summary":"Sensei Biotherapeutics, Inc. 宣布将公司名称变更为Faeth Therapeutics。这一更名标志着公司战略重心聚焦于推进其核心候选药物Piktor的研发。Piktor是一种口服疗法,旨在靶向癌症中最常发生异常改变的信号通路之一。公司此举旨在更好地反映其专注于开发变革性癌症治疗药物的新方向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FTH","SNSE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.faeththerapeutics.com","stockEarnings":[{"period":"1week","weight":0.6518},{"period":"1month","weight":0.3491},{"period":"3month","weight":-0.1862},{"period":"6month","weight":1.5918},{"period":"1year","weight":1.9777},{"period":"ytd","weight":1.2493}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0162},{"period":"3month","weight":0.1169},{"period":"6month","weight":0.0626},{"period":"1year","weight":0.2223},{"period":"ytd","weight":0.0758}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Faeth Therapeutics, Inc.是一家临床阶段的免疫疗法公司,于2017年12月1日在特拉华州注册成立。该公司是一家免疫肿瘤学公司,专注于癌症患者下一代疗法的发现和开发。通过TMAb(肿瘤微环境激活生物制剂)平台,公司正在开发高选择性疗法,旨在在肿瘤微环境中选择性地禁用免疫抑制信号或激活免疫刺激信号,以释放T细胞对抗肿瘤。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.040355},{"month":2,"riseRate":0.6,"avgChangeRate":0.423412},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.06831},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.097622},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.09801},{"month":6,"riseRate":0.5,"avgChangeRate":0.026226},{"month":7,"riseRate":0.4,"avgChangeRate":-0.061757},{"month":8,"riseRate":0.4,"avgChangeRate":0.038959},{"month":9,"riseRate":0.2,"avgChangeRate":-0.058884},{"month":10,"riseRate":0,"avgChangeRate":-0.117074},{"month":11,"riseRate":0.4,"avgChangeRate":-0.031651},{"month":12,"riseRate":0.4,"avgChangeRate":0.005246}],"exchange":"NASDAQ","name":"Faeth Therapeutics","nameEN":"Faeth Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Faeth Therapeutics(FTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Faeth Therapeutics(FTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Faeth Therapeutics,FTH,Faeth Therapeutics股票,Faeth Therapeutics股票老虎,Faeth Therapeutics股票老虎国际,Faeth Therapeutics行情,Faeth Therapeutics股票行情,Faeth Therapeutics股价,Faeth Therapeutics股市,Faeth Therapeutics股票价格,Faeth Therapeutics股票交易,Faeth Therapeutics股票购买,Faeth Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Faeth Therapeutics(FTH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Faeth Therapeutics(FTH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}